§ 02 — Comparison

Compare regulatory pathways side-by-side

Benchmark MAHMAH, GMPGMP, HTAHTA and pathway requirements across up to three markets.

Country A

Country B

Country C

Highlight differences

Criterion	🇲🇦Morocco	🇬🇧United Kingdom
Authority & dossier
Regulatory authority	DMP / AMMPS	MHRA
English submissions	No	Yes
CTD accepted	Yes	Yes
eCTD accepted	No	Yes
Reliance pathway	Available	Available
Reference agencies	FDA (US), EMA, MHRA (UK), Health Canada +5	FDA, EMA, Health Canada, Swissmedic +4
Lead pathway (timeline & fees) — Autorisation de Mise sur le Marché (AMM) — Standard Procedure · International Recognition Procedure (IRP)
Pathway name	Autorisation de Mise sur le Marché (AMM) — Standard Procedure	International Recognition Procedure (IRP)
Approval timeline	270–540 days	60–110 days
Application fee	MAD 30,000	GBP 35,305
Annual renewal	MAD 5,000	GBP 0
Local representative	Required	Not required
Local manufacturing	Not required	Not required
GMP inspection	Required	Not required
MAH & local presence
Local entity required	Yes	Yes
Local responsible person	Yes	Yes
RP role	Each pharmaceutical establishment must employ a Pharmacien Responsable (Responsible Pharmacist) registered with the Conseil National de l'Ordre des Pharmaciens, accountable for product quality, pharmacovigilance, recall and regulatory compliance. A Pharmacien Responsable de la Pharmacovigilance is the contact for the Centre Anti-Poison et de Pharmacovigilance (CAPM).	Qualified Person (Pharmacovigilance) — QPPV — must reside in the UK or EEA. UK Responsible Person (Import) for batch certification of products imported into GB. Local pharmacovigilance contact in the UK required for risk minimisation activities.
Accelerated pathways
Designations available	2 designations	4 designations
Examples	Reliance / Abridged — Expedited Review, Emergency Use Authorisation	Early Access to Medicines Scheme (EAMS), Conditional Marketing Authorisation, Authorisation under Exceptional Circumstances +1
Post-approval lifecycle
Variations framework	Variations are classified per DMP variation guidelines (broadly aligned with EU practice) into Minor (Type IA / IB — notification or prior-approval) and Major (Type II — prior-approval), and Extensions of registration. AMMPS transition is expected to further align variation classification with EU/WHO practice.	Variations classified per UK Variations Regulations (mirroring EU Reg 1234/2008): Type IA, IAIN, IB, II, and Extensions. MHRA Worksharing available for grouped variations across multiple authorisations.
Renewal cycle	AMM is valid for 5 years and renewable for further 5-year periods (potentially indefinite after first renewal, subject to favourable benefit/risk); renewal requires up-to-date CMC, safety, GMP and labelling information, plus payment of renewal fees.	Initial 5-year renewal; thereafter MA is granted for unlimited duration unless MHRA determines on PV grounds that one further 5-year renewal is justified.
Pharmacovigilance	The Centre Anti-Poison et de Pharmacovigilance du Maroc (CAPM, Rabat) coordinates national ADR reporting; Morocco is a member of the WHO Programme for International Drug Monitoring (Uppsala Monitoring Centre, since 1992). MAHs / local AMM holders must submit PSURs aligned to ICH E2C(R2), report serious ADRs within statutory timelines (15 days for serious unexpected ADRs), and maintain a Risk Management Plan (RMP) for new active substances and vaccines.	MHRA operates the Yellow Card Scheme for ADR reporting. PSURs follow the EU Reference Date list pre-Brexit, with MHRA UK-specific PSUR list since 2021. RMPs required for new MAs and significant variations. Black triangle (▼) for additional monitoring.
Unlicensed access
Named Patient Supply	Available	Available
Compassionate Use	Available	Available
Emergency Import	Available	Available
Parallel Import	Not permitted	Permitted
Clinical trials
CTA approval	Required	Required
Ethics approval	Yes	Yes
CTA timeline	60–120 days	30–60 days
GCP standard	ICH E6(R2) GCP; Law 28-13 on Biomedical Research on Human Subjects (Loi relative à la protection des personnes participant aux recherches biomédicales); Helsinki Declaration	ICH E6(R3) (MHRA adopted via Good Clinical Practice Guide; UK statutory instruments 2004/1031 as amended)
Pricing & reimbursement
Price regulation	Regulated	Regulated
Reference pricing	Yes	No
HTA required	No	Yes
HTA body	No formal national HTA agency; HTA capacity is being developed within the Ministry of Health and the Agence Nationale de l'Assurance Maladie (ANAM) under universal health coverage reforms.	NICE (England, Wales, NI), SMC (Scotland), AWMSG (Wales)

Verdict colours indicate lower, moderate, or higher regulatory burden — they're not value judgements on a market.

Authority & dossier

Regulatory authority

MoroccoDMP / AMMPS
United KingdomMHRA

English submissions

MoroccoNo
United KingdomYes

CTD accepted

MoroccoYes
United KingdomYes

eCTD accepted

MoroccoNo
United KingdomYes

Reliance pathway

MoroccoAvailable
United KingdomAvailable

Reference agencies

MoroccoFDA (US), EMA, MHRA (UK), Health Canada +5
United KingdomFDA, EMA, Health Canada, Swissmedic +4

Lead pathway (timeline & fees) — Autorisation de Mise sur le Marché (AMM) — Standard Procedure · International Recognition Procedure (IRP)

Pathway name

MoroccoAutorisation de Mise sur le Marché (AMM) — Standard Procedure
United KingdomInternational Recognition Procedure (IRP)

Approval timeline

Morocco270–540 days
United Kingdom60–110 days

Application fee

MoroccoMAD 30,000
United KingdomGBP 35,305

Annual renewal

MoroccoMAD 5,000
United KingdomGBP 0

Local representative

MoroccoRequired
United KingdomNot required

Local manufacturing

MoroccoNot required
United KingdomNot required

GMP inspection

MoroccoRequired
United KingdomNot required

MAH & local presence

Local entity required

MoroccoYes
United KingdomYes

Local responsible person

MoroccoYes
United KingdomYes

RP role

MoroccoEach pharmaceutical establishment must employ a Pharmacien Responsable (Responsible Pharmacist) registered with the Conseil National de l'Ordre des Pharmaciens, accountable for product quality, pharmacovigilance, recall and regulatory compliance. A Pharmacien Responsable de la Pharmacovigilance is the contact for the Centre Anti-Poison et de Pharmacovigilance (CAPM).
United KingdomQualified Person (Pharmacovigilance) — QPPV — must reside in the UK or EEA. UK Responsible Person (Import) for batch certification of products imported into GB. Local pharmacovigilance contact in the UK required for risk minimisation activities.

Accelerated pathways

Designations available

Morocco2 designations
United Kingdom4 designations

Examples

MoroccoReliance / Abridged — Expedited Review, Emergency Use Authorisation
United KingdomEarly Access to Medicines Scheme (EAMS), Conditional Marketing Authorisation, Authorisation under Exceptional Circumstances +1

Post-approval lifecycle

Variations framework

MoroccoVariations are classified per DMP variation guidelines (broadly aligned with EU practice) into Minor (Type IA / IB — notification or prior-approval) and Major (Type II — prior-approval), and Extensions of registration. AMMPS transition is expected to further align variation classification with EU/WHO practice.
United KingdomVariations classified per UK Variations Regulations (mirroring EU Reg 1234/2008): Type IA, IAIN, IB, II, and Extensions. MHRA Worksharing available for grouped variations across multiple authorisations.

Renewal cycle

MoroccoAMM is valid for 5 years and renewable for further 5-year periods (potentially indefinite after first renewal, subject to favourable benefit/risk); renewal requires up-to-date CMC, safety, GMP and labelling information, plus payment of renewal fees.
United KingdomInitial 5-year renewal; thereafter MA is granted for unlimited duration unless MHRA determines on PV grounds that one further 5-year renewal is justified.

Pharmacovigilance

MoroccoThe Centre Anti-Poison et de Pharmacovigilance du Maroc (CAPM, Rabat) coordinates national ADR reporting; Morocco is a member of the WHO Programme for International Drug Monitoring (Uppsala Monitoring Centre, since 1992). MAHs / local AMM holders must submit PSURs aligned to ICH E2C(R2), report serious ADRs within statutory timelines (15 days for serious unexpected ADRs), and maintain a Risk Management Plan (RMP) for new active substances and vaccines.
United KingdomMHRA operates the Yellow Card Scheme for ADR reporting. PSURs follow the EU Reference Date list pre-Brexit, with MHRA UK-specific PSUR list since 2021. RMPs required for new MAs and significant variations. Black triangle (▼) for additional monitoring.

Unlicensed access

Named Patient Supply

MoroccoAvailable
United KingdomAvailable

Compassionate Use

MoroccoAvailable
United KingdomAvailable

Emergency Import

MoroccoAvailable
United KingdomAvailable

Parallel Import

MoroccoNot permitted
United KingdomPermitted

Clinical trials

CTA approval

MoroccoRequired
United KingdomRequired

Ethics approval

MoroccoYes
United KingdomYes

CTA timeline

Morocco60–120 days
United Kingdom30–60 days

GCP standard

MoroccoICH E6(R2) GCP; Law 28-13 on Biomedical Research on Human Subjects (Loi relative à la protection des personnes participant aux recherches biomédicales); Helsinki Declaration
United KingdomICH E6(R3) (MHRA adopted via Good Clinical Practice Guide; UK statutory instruments 2004/1031 as amended)

Pricing & reimbursement

Price regulation

MoroccoRegulated
United KingdomRegulated

Reference pricing

MoroccoYes
United KingdomNo

HTA required

MoroccoNo
United KingdomYes

HTA body

MoroccoNo formal national HTA agency; HTA capacity is being developed within the Ministry of Health and the Agence Nationale de l'Assurance Maladie (ANAM) under universal health coverage reforms.
United KingdomNICE (England, Wales, NI), SMC (Scotland), AWMSG (Wales)